CD22 and primary cutaneous T-cell non-Hodgkin lymphoma: Analysis of CD22 and splice variant expression in CTCL lesions in situ revealed that the novel splice variant is expressed in 30% of the cases whereas only a few patients expressed wild-type CD22.